Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Phase 3

Conditions: Stage ⅠA Pancreatic Cancer
Stage ⅡA Pancreatic Cancer
Stage ⅠB Pancreatic Cancer
Stage ⅡB Pancreatic Cancer

Interventions: Drug: nab-paclitaxel
Drug: oxaliplatin
Drug: gemcitabine
Drug: folinic acid
Drug: fluorouracil

First Posted Date: 2015-07-23

Last Posted Date: 2016-08-11

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT02506842

Locations: 🇨🇳
Department of Pancreatic Surgery, Cancer Institute & Hospital, Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳
Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center,Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, Shanghai, China

and more 4 locations

Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Cisplatin
Drug: Fluorouracil
Radiation: Radiation therapy
Drug: Leucovorin

First Posted Date: 2015-07-17

Last Posted Date: 2015-07-17

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 54

Registration Number: NCT02500940

Locations: 🇨🇳
Taichung Vaterans General Hospital, Taichung, Taiwan

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Phase 3

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-FU
Drug: Placebo
Drug: Capecitabine

First Posted Date: 2015-07-10

Last Posted Date: 2023-04-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 763

Registration Number: NCT02494583

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Phase 3

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Raltitrexed
Drug: 5-fluorouracil
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2015-06-30

Last Posted Date: 2015-06-30

Lead Sponsor: Jiangsu Cancer Institute & Hospital

Target Recruit Count: 120

Registration Number: NCT02485548

Locations: 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Phase 2

Terminated

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Gastric Adenocarcinoma
Gastric Cancer

Interventions: Procedure: surgery
Procedure: FDG-PET
Drug: 5-FU
Drug: docetaxel
Drug: capecitabine
Radiation: 3D-CRT
Drug: Irinotecan
Radiation: IMRT

First Posted Date: 2015-06-30

Last Posted Date: 2019-09-11

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 5

Registration Number: NCT02485834

Locations: 🇺🇸
Regional Hematology and Oncology PA, Newark, Delaware, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Englewood Hospital and Medical Center, Englewood, New Jersey, United States

and more 68 locations

A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer

Phase 1

Terminated

Conditions: Rectal Cancer

Interventions: Drug: PEP503
Drug: 5-fluorouracil
Drug: capecitabine
Procedure: surgical resection
Radiation: Radiotherapy

First Posted Date: 2015-06-08

Last Posted Date: 2022-01-11

Lead Sponsor: PharmaEngine

Target Recruit Count: 32

Registration Number: NCT02465593

Locations: 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Sevacizumab
Drug: Irinotecan
Drug: 5-FU
Drug: Leucovorin

First Posted Date: 2015-05-25

Last Posted Date: 2016-04-20

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 36

Registration Number: NCT02453464

Locations: 🇨🇳
The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
The First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Adjuvant FEC Versus EP in Breast Cancer (MIG5)

Phase 3

Completed

Conditions: Chemotherapy, Adjuvant
Breast Cancer

Interventions: Drug: 5-fluorouracil
Drug: epirubicin
Drug: paclitaxel
Drug: cyclophosphamide

First Posted Date: 2015-05-21

Last Posted Date: 2015-05-21

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 1055

Registration Number: NCT02450058

Locations: 🇮🇹
Federico Castiglione, Alba, Italy
🇮🇹
Ornella Garrone, Cuneo, Italy
🇮🇹
Lucia Del Mastro, Genoa, Italy

and more 5 locations

HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC

Conditions: Hepatocellular Carcinoma
Injury; Blood Vessel, Hepatic, Artery

First Posted Date: 2015-05-06

Last Posted Date: 2019-08-20

Lead Sponsor: Ming Zhao

Registration Number: NCT02436044

Locations: 🇨🇳
Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Adenocarcinoma
Resectable Pancreatic Carcinoma

Interventions: Drug: Fluorouracil
Drug: Gemcitabine
Radiation: Image Guided Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Nab-paclitaxel
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2015-04-28

Last Posted Date: 2023-09-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 20

Registration Number: NCT02427841

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy